Free Trial

Halozyme Therapeutics (HALO) Earnings Date, Estimates & Call Transcripts

$45.48
-0.06 (-0.13%)
(As of 05/22/2024 ET)

Earnings Summary

Upcoming
Earnings Date
Aug. 13Estimated
Actual EPS
(Feb. 20)
$0.75 Missed By -$0.02
Consensus EPS
(Feb. 20)
$0.77
Skip Charts & View Estimated and Actual Earnings Data

HALO Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

HALO Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Halozyme Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20243$0.58$0.77$0.69 
Q2 20243$0.64$0.92$0.77 
Q3 20243$0.85$0.98$0.93 
Q4 20243$0.94$1.25$1.05 
FY 202412$3.01$3.92$3.43 
Q1 20251$0.85$0.85$0.85 
Q2 20251$0.90$0.90$0.90 
Q3 20251$1.01$1.01$1.01 
Q4 20251$1.15$1.15$1.15 
FY 20254$3.91$3.91$3.91 
Q1 20261$1.21$1.21$1.21 

HALO Earnings Date and Information

Halozyme Therapeutics last announced its earnings data on February 20th, 2024. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts' consensus estimates of $0.77 by $0.02. The business earned $230.04 million during the quarter, compared to analysts' expectations of $235.25 million. Halozyme Therapeutics has generated $2.42 earnings per share over the last year ($2.42 diluted earnings per share) and currently has a price-to-earnings ratio of 18.8. Earnings for Halozyme Therapeutics are expected to grow by 22.67% in the coming year, from $3.44 to $4.22 per share. Halozyme Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 13th, 2024 based off prior year's report dates.

Halozyme Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/13/2024
(Estimated)
------- 
2/20/2024Q4 2023$0.77$0.75($0.02)$0.85$235.25 million$230.04 million
11/6/2023Q3 2023$0.67$0.69+$0.02$0.77$219.47 million$216.03 million
8/8/2023Q2 2023$0.59$0.68+$0.09$0.80$201.91 million$221.04 million
5/9/2023Q1 2023$0.44$0.43($0.01)$0.57$174.20 million$162.14 million
2/21/2023Q4 2022$0.43$0.44+$0.01$0.46$186.07 million$181.50 million
11/8/2022Q3 2022$0.49$0.70+$0.21$0.96$187.87 million$208.98 million
8/9/2022Q2 2022$0.47$0.50+$0.03$0.84$156.00 million$152.37 million      
5/10/2022Q1 2022$0.45$0.43($0.02)$0.43$128.25 million$117.30 million    
2/22/2022Q4 2021$0.35$0.39+$0.04$0.32$97.10 million$102.00 million
11/2/2021Q3 2021$0.42$1.48+$1.06($0.44)$101.94 million$115.83 million    
8/9/2021Q2 2021$0.43$0.62+$0.19$0.64$104.08 million$136.50 million    
5/10/2021Q1 2021$0.32$0.37+$0.05$0.49$84.88 million$89.02 million    
2/23/2021Q4 2020$0.56$0.50($0.06)$0.50$120.75 million$121.70 million    
11/2/2020Q3 2020$0.20$0.25+$0.05$0.25$59.35 million$65.30 million    
8/10/2020Q2 2020$0.25$0.19($0.06)$0.19$65.81 million$55.22 million  
5/11/2020Q1 2020($0.02)($0.04)($0.02)($0.04)$42.96 million$25.30 million    
2/24/2020Q4 2019($0.18)($0.24)($0.06)($0.24)$55.69 million$53.70 million  
11/12/2019Q3 2019($0.12)($0.1712)($0.0512)($0.17)$54.96 million$46.20 million  
8/6/2019Q2 2019($0.17)($0.1006)+$0.0694($0.10)$42.94 million$39.10 million    

Halozyme Therapeutics Earnings - Frequently Asked Questions

When is Halozyme Therapeutics's earnings date?

Halozyme Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 13th, 2024 based off last year's report dates. Learn more on HALO's earnings history.

Did Halozyme Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Halozyme Therapeutics (NASDAQ:HALO) missed the analysts' consensus estimate of $0.77 by $0.02 with a reported earnings per share (EPS) of $0.75. Learn more on analysts' earnings estimate vs. HALO's actual earnings.

How much revenue does Halozyme Therapeutics generate each year?

Halozyme Therapeutics (NASDAQ:HALO) has a recorded annual revenue of $829.25 million.

How much profit does Halozyme Therapeutics generate each year?

Halozyme Therapeutics (NASDAQ:HALO) has a recorded net income of $281.59 million. HALO has generated $2.42 earnings per share over the last four quarters.

What is Halozyme Therapeutics's price-to-earnings ratio?

Halozyme Therapeutics (NASDAQ:HALO) has a trailing price-to-earnings ratio of 18.79 and a forward price-to-earnings ratio of 13.22. The price/earnings-to-growth ratio is 0.5.

What is Halozyme Therapeutics's EPS forecast for next year?

Halozyme Therapeutics's earnings are expected to grow from $3.44 per share to $4.22 per share in the next year, which is a 22.67% increase.


More Earnings Resources from MarketBeat

This page (NASDAQ:HALO) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners